Sinusitis Treatment Market 2022 – Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Market Size & Forecast 2030

Page: 355 | Report Code: LS22310101 | Research Suite: Report (PDF) & Market Data (Excel)

Request Sample Pages to Get Table of Content

The global sinusitis treatment market was valued at USD 3.0 billion in 2021 and is projected to expand at a CAGR of 5.2% during the forecast period of 2022-2030.


As per the reports of Sinus & Allergy Wellness Center 2021, more than 30.0 million people are affected by sinusitis in the U.S. each year. Sinusitis is observed in children as well as adults and is one of the most common infections of the upper respiratory tract system worldwide.


Sinusitis is an inflammation of the mucosal lining of the paranasal sinuses located in the skull. It is caused by virus, fungi, bacteria and microbes. Viral sinusitis is the common form of sinusitis and does not require antibiotics. Bacterial sinusitis, however, is lesser prevalent than viral sinusitis and requires doses of antibiotics.


Sinusitis can be acute, sub-acute, or chronic. Usually, the condition causes extreme discomfort, and in uncontrolled advanced stages, it can also lead to complications such as brain abscess and meningitis if it is not treated or detected. The first-line treatment of sinusitis is antibiotics followed by decongestants and surgery at severe stages.



Factors such as the proliferating base of common cold and sinusitis patients across the globe, the growing demand for enhanced diagnostic practices as well as development of advanced antibiotics, the surging upper respiratory tract infections cases across the world and the increasing pollution levels especially across the developing regions are the primary factors driving the growth of the global sinusitis treatment market.


Additionally, companies and hospitals' growing initiatives and education programs focused on creating awareness among patients regarding the need for a potent therapeutic approach for sinusitis management and treatment have been successful increasing the adoption rate of treatments globally. In turn, the drug manufacturers are forced to develop and commercialize new therapeutic measures and bring advanced and innovative respiratory treatments and diagnostic procedures in the healthcare system. This has led to the advent of advanced devices such as an enhanced intra-nasal drug delivery which aids in the improvement of patient’s quality of life and the new nasal spray which delivers drugs in hard-to-reach cavities of patient’s sinuses.  Others devices that enable patients to treat themselves at home to minimize symptoms of chronic sinusitis in its early stages are also underway. The increasing number of technological innovations by manufacturers is thus; set to bring incremental growth opportunities for the global sinusitis treatment market in the upcoming years.


Moreover, the investments made by drug manufacturers on R&D activities for receiving regulatory approvals by government authorities have been rising tremendously since the last few years. As a result, the number of approvals is also growing. This rising investment and approval rate of drugs and treatments are expected to further bolster the growth of the market during the forecast period.


Furthermore, other factors such as innovation in diagnostic tests and antibodies production, the surging number of factors inclining people to sinusitis, the increasing use of various medications for treatment such as nasal sprays, nasal corticosteroids, and decongestants and the burgeoning demand for better treatment options for acute and chronic sinusitis and other associated disorders such as asthma in same patients are expected to further augment the growth of the global sinusitis treatment market during the forecast period.


However, factors such as the high cost of diagnostic tests, the side effects associated with corticosteroids, and the growing concerns regarding affordability and availability of the tests are anticipated to restrain the growth of the global sinusitis treatment market up to some extent during the forecast period.



By Disease

·         Acute Sinusitis

·         Sub-acute Sinusitis

·         Chronic Sinusitis

By Treatment

·        Analgesics

·        Antibiotics

o   Penicillin/ Β-lactamase inhibitor combinations

o   Macrolide

o   Quinolone

o   Cephalosporin

·        NSAIDS

·        Decongestant and mucolytic

o   Corticosteroids

o   Antihistamines

o   A1 receptor agonist

o   Imidazoline derivatives

·        Nasal irrigation

·        Surgery

o   Endoscopy

o   Balloon Sinusplasty

By Route of Administration

·         Topical

·         Nasal

·         Oral

·         Injectable

By Distribution Channel

·         Online Pharmacies

·         Retail Pharmacies

·         Hospital Pharmacies


By Region

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East and Africa

Based on disease, the acute sinusitis segment accounted for the largest market share of 36.0% in the global sinusitis treatment market in 2021 and is projected to further retain its dominance in the market by expanding at a CAGR of 4.1% during the forecast period. The segment's growth can be attributed to the increasing incidences of common cold & flu cases among people leading to enhanced cases of acute sinusitis globally.


Based on route of administration, the oral segment held the largest market share of 61.0% in the global sinusitis treatment market in 2021. The segment is anticipated to further maintain this trend over the forecast period as it is the most commonly used route of administration due to its several advantages, including feasibility, ease of administration, intensified immune response, and convenience.


Based on distribution channel, the retail pharmacies segment led the global sinusitis treatment market in 2021 by acquiring a market share of 45.0%. It is estimated that the segment will continue to lead the market further during the forecast period of 2022-2030. However, the hospital pharmacies segment is expected to witness growth at the highest CAGR in the market during the forecast period owing to the availability of funds and growing demand from the patients.


Based on treatment, the antihistamines sub-segment held over 32.0% market share and dominated in the global sinusitis treatment market in 2021. The segment is predicted to further register growth at a CAGR of 3.85% from 2023 to 2030. The growth of the segment can be attributed to the growing usage of these drugs to relieve allergy, cold and sinus symptoms. The antibiotics segment held the second largest share in the global market in 2021 and is expected to witness substantial growth in the market during the forecast period. This is because due to the surging consciousness among people regarding antibiotics, their easily availability and the escalating number of companies investing in the development of antibiotics. However, the decongestant & mucolytic and NSAIDS segments are expected to witness the fastest growth in the market during the forecast period.



The North American region accounted for the largest share in the global sinusitis treatment market in 2021 followed by Europe. The region is expected to further maintain its position at the top during the forecast period. The growth of the market in the region can be attributed to which the growing incidence sinusitis and chronic diseases cases in the region, the high presence of well-established players, the rising awareness level, the increasing adoption of new technologies and the growing developments in sinus surgery in the region. The major contributor to the growth of the region is the United States.


The European region held the second largest share in the global sinusitis treatment market in 2021 and is expected to grow at a robust growth rate over the forecast period further.  The growth in the region can be attributed to the burgeoning number of invasive bacterial diseases and the increasing number strategic partnership between academic research institutes and major pharmaceutical players for the formulation and development of medicines employed for the treatment of sinusitis infection in the region.


The Asia Pacific region is predicted to be the fastest-growing regional sinusitis treatment market during the forecast period. The growth in the region can be attributed to the increasing cases of acute bacterial sinusitis infection, the soaring pollution levels and the advancing healthcare infrastructure in the region. Furthermore, the rapidly proliferating population, the surging disposable incomes and healthcare spending of people, the high prevalence of unhealthy lifestyles, and the growing number of R&D activities in the region are also expected to significantly contribute to the growth of the global sinusitis treatment market during the forecast period. The major contributors to the region include India, China and Japan.



·         Novartis AG

·         Teva Pharmaceutical Industries Ltd.

·         Sanofi S.A.

·         Abbott Laboratories Inc.

·         Bayer AG

·         Eli Lilly and Company

·         Sun Pharmaceutical Industries Inc.

·         Pfizer Inc.

·         Janssen Pharmaceuticals Inc.

·         Dr. Reddy's Laboratories Inc.

·         Bristol-Myers Squibb

·         Merck & Co. Inc.

·         AstraZeneca plc

·         GlaxoSmithKline plc.

·         Hikma Pharmaceuticals plc

·         Mylan N.V.

·         Olympus Corporation

·         Medtronic plc

·         Stryker

·         Cipla Ltd

·         Other players

Buy Report

  • $1990
  • $3150